Posted by Michael Wonder on 06 Mar 2023
Bristol Myers Squibb receives European Commission approval of Reblozyl (luspatercept) for anaemia in adult patients with non-transfusion-dependent beta thalassaemia
3 March 2023 - Third authorised indication in Europe for Reblozyl, a first in class treatment for patients with diseases impacted by anaemia.
Bristol Myers Squibb today announced that the European Commission has granted full marketing authorisation for Reblozyl (luspatercept), a first in class therapeutic option, for treatment in adult patients of anaemia associated with non-transfusion-dependent beta thalassaemia.
